Healthcare Providers and Services
Company Overview of Castle Biosciences Incorporated
Castle Biosciences Incorporated develops and commercializes diagnostic and prognostic tests for cancers. It offers DecisionDx-Melanoma, a gene expression profile test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue; DecisionDx-UM test to measure the activity or gene expression of a set of 15 genes within an ocular melanoma tumor to identify the likelihood of metastasis; and DecisionDx-EC test, which analyzes the localization of three protein biomarkers in a patient’s tumor to classify the cancer as either responsive to or resistant to pre-surgical chemoradiotherapy. The company also provides DecisionDx-Mes...
820 South Friendswood Drive
Friendswood, TX 77546
Founded in 2007
Key Executives for Castle Biosciences Incorporated
Founder, Chief Executive Officer, President and Director
Vice President of Operations
Director of Reimbursement
Compensation as of Fiscal Year 2015.
Castle Biosciences Incorporated Key Developments
Castle Biosciences Incorporated Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-10-2016 02:15 PM
Jan 19 16
Castle Biosciences Incorporated Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-10-2016 02:15 PM. Venue: The Waldorf Astoria, New York, New York, United States.
Castle Biosciences Incorporated Presents at 27th Annual Piper Jaffray Healthcare Conference, Dec-02-2015 12:50 PM
Nov 25 15
Castle Biosciences Incorporated Presents at 27th Annual Piper Jaffray Healthcare Conference, Dec-02-2015 12:50 PM. Venue: Lotte New York Palace, New York, New York, United States. Speakers: Derek J. Maetzold, Founder, Chief Executive Officer, President and Director.
Castle Biosciences, Inc. Announces Executive Appointments
Nov 3 15
Castle Biosciences Inc. announced the appointment of Federico A. Monzon, M.D., FCAP, to the newly created role of Chief Medical Officer. The company also announced the appointment of Greg Schafer to Executive Director of Managed Care. Dr. Monzon is a molecular pathologist with extensive experience translating novel genomic technologies into clinical molecular tests. Most recently, he served as Medical Director of Oncology and Medical Director of Latin America at Invitae Corporation. Mr. Schafer has a strong background in managed care, sales and marketing, most recently serving as Head of Managed Care at Invitae Corporation, where he developed reimbursement and claims appeal strategy and increased in-network contracted providers.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 15, 2015
Most Searched Private Companies
Sponsored Financial Commentaries